Skip to content

Prime Medicine PRME Other accrued liabilities

Other accrued liabilities at other companies

Opus Genetics logo
Opus GeneticsIRD
Precigen logo
PrecigenPGEN
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's other accrued liabilities?
Prime Medicine (PRME) reported other accrued liabilities of $2.15M in Q1 2026.
How has Prime Medicine's other accrued liabilities changed year-over-year?
Prime Medicine's other accrued liabilities decreased by 20.9% year-over-year, from $2.72M to $2.15M.
What is the long-term trend for Prime Medicine's other accrued liabilities?
Over 4 years (2021 to 2025), Prime Medicine's other accrued liabilities has grown at a 57.2% compound annual growth rate (CAGR), from $279K to $1.7M.